导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.81% | 3012/4773 |
| 近一周 | -2.19% | 1449/5462 |
| 近一月 | -4.31% | 2379/5421 |
| 近一季 | -8.03% | 2645/5209 |
| 近半年 | -3.73% | 2304/4920 |
| 近一年 | -0.85% | 2787/4366 |
| 近两年 | 41.16% | 1832/2954 |
| 近三年 | 23.11% | 1361/2253 |
| 成立以来 | 30.18% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.56% 3283/4961 |
11.64% 2311/5312 |
- - |
- - |
| 2025 | 17.78% 2353/4813 |
-1.07% 2570/3635 |
1.78% 2151/4076 |
17.26% 2538/4524 |
-0.24% 2432/4813 |
| 2024 | 15.72% 893/3463 |
2.51% 763/2808 |
-1.29% 1024/3014 |
16.47% 1447/3129 |
-1.81% 1842/3463 |
| 2023 | -9.49% 1175/2656 |
4.28% 998/2280 |
-4.10% 1045/2385 |
-3.11% 852/2515 |
-6.59% 1839/2655 |
| 2022 | -19.41% 846/2207 |
-13.85% 855/1919 |
6.60% 652/2016 |
-13.77% 969/2113 |
1.77% 1153/2208 |
| 2021 | -3.56% 913/1822 |
-3.09% 757/1255 |
3.99% 938/1330 |
-5.56% 824/1466 |
1.33% 963/1822 |
| 2020 | 28.41% 560/1250 |
-9.66% 705/1028 |
13.10% 650/1067 |
11.52% 439/1164 |
12.69% 441/1184 |
| 2019 | 36.41% 358/1092 |
26.74% 381/739 |
-0.13% 217/788 |
0.80% 463/850 |
6.92% 515/918 |
| 2018 | - - |
- - |
-8.48% 220/631 |
-1.02% 225/660 |
-11.88% 376/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 农银沪深300指数C VS. 长安沪深300非周期A(740101) |